Background: High sensitive CRP (hs-CRP) is used as a marker of systemic inflammation in chronic obstructive pulmonary disease (COPD). However, we hypothesize that the raised hs-CRP is not closely related to the multiple consequences of COPD. This study was undertaken to investigate the association of COPD assessment test (CAT) score with SpO 2 , FEV 1 , body mass index (BMI), obstruction, dyspnea and exercise capacity (BODE) index and COPD exacerbation rate and compare it with the association to serum hs-CRP level. Materials and Methods: Sixty patients with stable COPD referred to the pulmonology clinic of Ardabil Imam Khomeini Hospital were included in this study. SpO 2 , 6-minute walk distance (6MWD), body mass index, BODE index, and pulmonary function test as well as exacerbation rate were determined in COPD patients. Then, the CAT questionnaire was completed by patients. Serum level of hs-CRP was measured in all patients and 15 controls. We statistically compared the relationships and correlations among the variables. Results: Hs-CRP level was significantly raised in patients (P=0.005). In these patients, the correlation of hs-CRP level with BODE index was significant (P=0.008). However, the correlation of hs-CRP with SpO 2 and FEV 1 was not significant (P=0.47 and P=0.17, respectively). Also, the correlation of CAT score with SpO 2 , FEV 1 , BODE index, and exacerbation rate in the previous year was significant (P<0.001, P<0.001, P<0.001 and P=0.017, respectively). Conclusion: SpO 2 , FEV 1 , BODE index and exacerbation rate are more correlated with CAT scores than with the serum level of hs-CRP in stable COPD patients. The findings of this study should be considered in management of stable COPD patients.
INTRODUCTION
COPD is the fourth cause of mortality afflicting over 200 million people around the world (1, 2) . It is characterized by irreversible airflow limitation and is associated with a systemic inflammatory response. It is estimated to rank the third most common cause of death in the world by 2020 (3). COPD has a major negative impact on health and quality of life (4) . There is a list of major risk factors for COPD in which, smoking holds the first rank (5) . Other relatively less common risk factors for COPD include respiratory infections, occupational exposure, air pollution, and genetics (6) .
It is well known that in patients with COPD, systemic inflammation in addition to local airway inflammation TANAFFOS Ghobadi H, et al. 35 Tanaffos 2015; 14 (1) : [34] [35] [36] [37] [38] [39] [40] [41] depending on the severity of COPD, contribute to pulmonary and extra-pulmonary complications of the disease such as pulmonary function impairment, exercise intolerance (even regardless of lung function impairment level), disease exacerbation, hypoxemia, muscle atrophy, activity confinement, cachexia, and osteoporosis (7) (8) (9) (10) .
The most common causes of mortality in patients with COPD include respiratory insufficiency and cardiovascular complications; both of which can be ascribed to the systemic inflammation and its severity (11) .
Systemic inflammation can be determined with markers of inflammation such as CRP, interleukins (IL), and TNFα. Among these markers, hs-CRP is as an important one and is a widely accepted biomarker related to the airflow obstruction (7).
However, the potential role of hs-CRP as a marker to reflect all aspects of pulmonary and extra-pulmonary complications in COPD and its prognostic value in COPD need further investigation.
COPD assessment test (CAT) is a new questionnaire for COPD patients. It is a simple method for assessing the impact of COPD on health and has similar discriminative properties to the much more complex St. George`s Respiratory Questionnaire (SGRQ) to measure the impact of COPD on individual patient's health (12) (13) (14) (15) .
This study was undertaken to investigate the association of hs-CRP levels and CAT scores with COPD impairment variables such as hypoxia severity (SpO 2 ), FEV 1 , BODE index and the frequency of exacerbations.
MATERIALS AND METHODS
This cross sectional study was conducted on 60 patients with COPD diagnosed on the basis of the criteria suggested by the American Thoracic Society (ATS) for diagnosis and treatment of COPD (16) . All the patients with symptoms suggestive of COPD underwent spirometry before and after inhalation of bronchodilator.
All the participants chosen for this study had stable COPD and had been referred to the pulmonology clinic of Ardabil Imam Khomeini Hospital. All subjects with a history of asthma, bronchiectasis, tuberculosis and debilitating inflammatory diseases such as arthritis, connective tissue disorders, inflammatory bowel disease or malignancy and patients in the exacerbation phase or with a hospitalization record during the past two months were excluded from this study.
All participants signed a consent form for participation in the study. Subsequently, their demographic data (including sex, weight, height, age and the amount and duration of smoking) were recorded.
Each patient was assigned a BODE score. The BMI was calculated and the degree of airflow obstruction was determined by means of FEV 1 ; dyspnea was determined using the MMRC dyspnea scale and exercise capacity was Oxygen saturation was measured in all patients by pulse-oximetry. Exacerbations were defined using the criteria developed by Global Initiative for Obstructive Lung Disease (GLOD) (18) .
CAT is a recently introduced, patient-completed instrument to assess and quantify health-related quality of life and symptom burden in patients with COPD (13, 19) . It comprises 8 questions, each presented as a semantic 6-point (0-5) differential scale, providing a total score out of 40 (20) . All patients completed the CAT questionnaire. The total CAT score was calculated for each individual by summing the points for each variable. The CAT score was classified into four groups of 1) low, 2) medium, 3) high, and 4) very high based on the impact level of disease on health status (13) . Differences between means were analyzed with Student's t-test and reported with 95% confidence interval.
ANOVA was applied with 95% confidence interval for the estimation of differences. In order to evaluate the correlation between parametric variables, the Pearson's correlation coefficient was utilized. SPSS was used for analysis of data. P value less than 0.05 in all analyses was considered statistically significant.
RESULTS
A total of 60 patients were recruited out of which, 54 (90%) were males and 6 (10%) were females. Also, 15 healthy subjects comprised the control group. The mean ± Quartile IV (7-10) 6(10%) 7.50±0.55 Tables 2 and 3 display hs-CRP and CAT score relationships with disease severity variables. The analysis also showed a weak correlation between serum hs-CRP level and CAT score (r=0.25, P=0.05). Hs-CRP is an inflammatory factor, which is released by hepatocytes and its elevation can be a sign of severity of systemic inflammation. Some researchers showed a correlation between hs-CRP level and FEV 1 (25) (26) (27) .
However in the present study there was no significant correlation between hs-CRP and FEV 1 . In our opinion, the serum hs-CRP does not adequately reflect all the pulmonary and extra-pulmonary manifestations of disease.
For example, in this study the serum level of hs-CRP did not show a significant correlation with exacerbation rate.
The patients' BODE index was also calculated and the gained score was placed in the fourth quartile. The results
showed that CAT score and hs-CRP levels in patients had a highly significant relationship with their BODE scores (P<0.001 and P=0.008, respectively). The results of the current study manifested that as hs-CRP level increased the amount of muscular activity and walked distance in 6 minutes decreased.
In the current study, the patients' dyspnea was examined using MMRC scoring system and the patients 
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